Skip to content
Medical Health Aged Care

Dr Fei Sim re-elected as National President

Pharmaceutical Society of Australia (PSA) 2 mins read

The Pharmaceutical Society of Australia (PSA) has re-elected Dr Fei Sim FPS as National President and Chair of the National Board in Canberra today.

The Board also elected Caroline Diamantis MPS and Benjamin Marchant MPS as National Vice-Presidents for the term beginning 1 July 2023. Dr Shane Jackson FPS was also appointed to lead PSA’s approach to the Community Pharmacy Agreement and will remain a part of the Board executive.  

PSA Interim Chief Executive Officer Nick Foster welcomed incoming Board Directors Dr Natalie Soulsby FPS, Amanda Cross MPS and Helen Benson MPS.

“I am excited at to work with a PSA board with such a wealth of experience across all sectors of pharmacy,” Mr Foster said.

“I particularly welcome new Directors Dr Natalie Soulsby, Amanda Cross and Helen Benson, who are all experienced, passionate pharmacists who bring a wealth of experience to our organisation. 

“PSA is proud to welcome a Board that reflects our profession, with more than half of our incoming Board being women.

“I look forward to working closely with the newly appointed Board and our re-elected President to best support Australia’s pharmacists.”

Dr Sim, who was first elected as President in June 2021, said it was an honour to be re‑elected and continue her advocacy for pharmacists during a time of rapid change.

“Despite the challenges that our profession faces, I am confident in the future of our profession,” Dr Sim said.

“With the support of the PSA Board, we continue to work toward a future that recognises the skills and expertise of pharmacists and allows us to practice to our top of scope.

“This is my priority and the priority of our entire team.

“Thank you, PSA members, for your support. I am humbled and proud to be able to continue leading you and our profession.

“I would also like to thank retiring Board members Michelle Lynch FPS, Warwick Plunkett FPS, Andrew Sluggett FPS, and Deanna Mill MPS for their service to our profession,” Dr Sim concluded.

The incoming Board of Directors includes:

  • Dr Fei Sim FPS, National President (Western Australia)
  • Caroline Diamantis MPS, National Vice-President (New South Wales)
  • Benjamin Marchant MPS, National Vice-President (Victoria)
  • Dr Shane Jackson FPS, Board Executive member (Tasmania)
  • Helen Benson MPS, Board Director (New South Wales)
  • Amanda Cross MPS, Board Director (Victoria)
  • Prof. Mark Naunton MPS, Board Director (Australian Capital Territory)
  • Dr Natalie Soulsby FPS, Board Director (South Australia)
  • Bridget Totterman MPS, Board Director (Queensland)

New appointments will commence on 1 July 2023.

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: [email protected]

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

More from this category

  • Medical Health Aged Care, Science
  • 24/06/2025
  • 08:05
WEHI

Barcodes uncover early blueprints of our cellular origins

A landmark study by WEHI scientists has shed new light on one of the most fundamental mysteries of biology: how cells divide and grow…

  • Contains:
  • General News, Medical Health Aged Care
  • 24/06/2025
  • 07:00
Monash University

Education status associated with reduced life expectancy and quality of life in Australia: new study

Australian males aged 25 years with a high level of education (completion of a bachelor’s degree or above) have 7.3 years greater life expectancy…

  • Contains:
  • Medical Health Aged Care
  • 24/06/2025
  • 06:00
Vertex

Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People with Cystic Fibrosis

–With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time – – The expanded listing includes an additional 271 mutations, many of them rare – Sydney, 24 June 2025 – Vertex Pharmaceuticals today announced that as of 1 July 2025, the funding of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be expanded on the Pharmaceutical Benefits Scheme (PBS) to include patients with cystic fibrosis aged 2years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive to elexacaftor/tezacaftor/ivacaftor potentiation…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.